Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | ROR1 | Q01973 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704334 | 0.83 | MKNK1 (0.46) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL24496139 | 0.82 | MKNK1 (0.43) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL10207631 | 0.80 | MKNK1 (0.44) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL588504 | 0.80 | MKNK1 (0.44) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL19840388 | 0.79 | MKNK1 (0.49) | MKNK1DYRK1AKLK7 | |
| SCHEMBL588691 | 0.79 | MKNK1 (0.49) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL29890013 | 0.76 | MKNK1 (0.41) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL16201030 | 0.76 | MKNK1 (0.41) | MKNK1CSF1RROR1DYRK1AABL1 | |
| SCHEMBL24491379 | 0.75 | CSF1R (0.49) | CSF1RROR1ABL1 | |
| SCHEMBL23800981 | 0.73 | MKNK1 (0.38) | MKNK1CSF1RROR1DYRK1AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | MKNK1 2114/4885CSF1R 436/4885ROR1 8/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | MKNK1 2020/4885CSF1R 181/4885ROR1 16/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | MKNK1 1015/4885CSF1R 350/4885ROR1 12/4885 |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | MKNK1 1015/4885CSF1R 350/4885ROR1 12/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | MKNK1 925/4885CSF1R 117/4885ROR1 42/4885 |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | MKNK1 2161/4885CSF1R 415/4885ROR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.